-+ 0.00%
-+ 0.00%
-+ 0.00%

Ionis says Phase 3 eplontersen trial in ATTR-CM misses primary endpoint

PUBT·07/09/2026 06:01:16
Listen to the news
Ionis says Phase 3 eplontersen trial in ATTR-CM misses primary endpoint
  • Ionis reported its Phase 3 CARDIO-TTRansform trial of eplontersen in ATTR-CM missed the primary endpoint versus placebo through Week 140.
  • No statistically significant benefit on the composite of CV mortality and recurrent CV events in a population largely treated with stabilizers.
  • Prespecified monotherapy subgroup showed a nominally significant hazard ratio of 0.71; no effect in patients on stabilizers at baseline.
  • Safety profile remained favorable; large, sustained transthyretin reductions observed.
  • Full results slated for presentation at the European Society of Cardiology Congress in August 2026.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ionis Pharmaceuticals Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202607090200BIZWIRE_USPR_____20260708_BW332180) on July 09, 2026, and is solely responsible for the information contained therein.